GNAO1 and drug-induced dyskinesia: On this basis, a clear assessment of the direction of the alteration of cAMP (increase vs. decrease) resulting from different GNAO1 mutations is crucial for establishing inclusion and exclusion criteria in clinical trials with caffeine in GNAO1-related dyskinesia.